Skip to main content
Clinical Trials/NCT05527080
NCT05527080
Recruiting
N/A

Development of Motility and Cognition in Infants

Helsinki University Central Hospital1 site in 1 country250 target enrollmentOctober 1, 2021

Overview

Phase
N/A
Intervention
Not specified
Conditions
Neurodevelopmental Disorders
Sponsor
Helsinki University Central Hospital
Enrollment
250
Locations
1
Primary Endpoint
neurological development
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

PILKE study uses wearables for assessing motor development in infants in order to define functional growth trajectories in the normal infants and infants at risk of neurological compromise. In addition, PILKE studies correlation of early motor development to later neurocognitive development.

Detailed Description

PILKE study builds on the recent development of an infant wearable, MAIJU, a multisensor garment that can be used to quantify infants posture and movement patterns out-of-hospital. The study will recruit typically developing infants (control group) and infants with an identified or suspected risk of neurodevelopmental compromise, as well as infants undergoing orthopedic follow-up for hip issues. Infants will be examined and treated according to clinical routine practise, while MAIJU and other novel measures are added to monitor aspects of neurodevelopment. Recordings with MAIJU will be done every 6-8 weeks from about 5 months to 18 months of age, and the neuropsychological outcome is assessed using Bayley scales at two years of age. The study is observational by design, and the trajectories of motor performance are compared to other clinically identified measures of development.

Registry
clinicaltrials.gov
Start Date
October 1, 2021
End Date
December 30, 2027
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Sampsa Vanhatalo

professor in clinical neurophysiology

Helsinki University Central Hospital

Eligibility Criteria

Inclusion Criteria

  • age at enrollment 5-8mos
  • typically developing

Exclusion Criteria

  • all neurologically significant medical histories during pregnancy, at birth or postnatally
  • suspicion of developmental delay
  • suspicion or diagnosis of syndromes with neuromotor symptoms

Outcomes

Primary Outcomes

neurological development

Time Frame: 12 months

Binary information (normal vs abnormal) is taken from the postnatal follow-up clinic inspection that is done according to the national standards (www.thl.fi)

neurocognitive development

Time Frame: 24 months

The total score of the neuropsychological examination Bayley scales III will be used

Study Sites (1)

Loading locations...

Similar Trials